Light Chain Amyloidosis Clinical Trials and Treatments

Light Chain Amyloidosis results from clonal plasma cell proliferation producing excessive amounts of misfolded immunoglobulin light chains (kappa or lambda) that cannot be properly degraded. These misfolded proteins aggregate to form amyloid fibrils that deposit in various tissues, causing progressive organ dysfunction. The heart is affected in approximately 50-70% of patients, leading to restrictive cardiomyopathy with diastolic dysfunction, arrhythmias, and sudden cardiac death.

The most common symptoms of Light Chain Amyloidosis include Fatigue and weakness, Shortness of breath and heart failure symptoms, Swelling in ankles, feet, legs, and abdomen (edema), Numbness, tingling, or pain in hands and feet (peripheral neuropathy), Proteinuria (protein in urine) and kidney dysfunction, among others. Approximately 600-1,000 new cases per year in the United States; median age of diagnosis is 63 years. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Light Chain Amyloidosis from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Light Chain Amyloidosis treatment is advancing rapidly with multiple research directions offering hope. Proteasome inhibitors and immunomodulatory drugs work together to target the underlying plasma cell clones, while monoclonal antibodies provide additional approaches to controlling the disease.

Yes. As of October 21, 2026, 1 FDA-approved medicine has a current label that names Light Chain Amyloidosis: Darzalex Faspro (daratumumab and hyaluronidase-fihj), first approved in 2021. Corticosteroids and immune globulins count once each.

Light Chain Amyloidosis is an acquired condition, not an inherited one. Caused by an acquired clonal plasma cell disorder, not an inherited gene; TTR sequencing is done only to rule out hereditary ATTR. Approximately 600-1,000 new cases per year in the United States; median age of diagnosis is 63 years.

Eligibility for Light Chain Amyloidosis clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Light Chain Amyloidosis clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.